Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$310,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
Minnesota
Government bodies contacted
4
Lobbying activity
3
Continued funding for the C.W. Bill Young Cell Transplantation Program. Increased funding to expand patient access to transplants. Increased medical research funding.
Donated bone marrow/cell transportation for life-saving transplant.
Reauthorization of C.W. Bill Young Cell Transplantation Program (House and Senate), H.R. 5160/S. 4109. Clinical Trial Modernization Act, H.R. 3521, S. 4440. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment including support for and remote access to trials.